Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $34.6 million versus the consensus estimate of $34.23 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.